Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer.
作者信息
Riess Jonathan W, Lara Primo N, Gandara David R
机构信息
Jonathan W. Riess, Primo N. Lara Jr, and David R. Gandara, University of California Davis Comprehensive Cancer Center, Sacramento, CA.
出版信息
J Clin Oncol. 2016 Nov 1;34(31):3717-3718. doi: 10.1200/JCO.2016.69.0040.
Abstract
摘要
相似文献
1
Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer.小细胞肺癌免疫检查点阻断的理论与实践
J Clin Oncol. 2016 Nov 1;34(31):3717-3718. doi: 10.1200/JCO.2016.69.0040.
2
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?单独使用PD-1检查点阻断疗法或联合使用PD-1和CTLA-4阻断疗法作为肺癌的免疫疗法？
Expert Opin Biol Ther. 2017 Mar;17(3):305-312. doi: 10.1080/14712598.2017.1280454. Epub 2017 Jan 18.
3
Immune checkpoint inhibitors in lung cancer: current status and future directions.肺癌中的免疫检查点抑制剂：现状与未来方向。
Chin Clin Oncol. 2017 Apr;6(2):17. doi: 10.21037/cco.2017.02.05.
4
Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade.小细胞肺癌对免疫化疗有反应，随后进行 PD-1 阻断。
Oncoimmunology. 2021 Nov 2;10(1):1996686. doi: 10.1080/2162402X.2021.1996686. eCollection 2021.
5
PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.非小细胞肺癌中的PD-1/PD-L1免疫检查点阻断
Clin Adv Hematol Oncol. 2015 Oct;13(10):676-83.
6
Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.小细胞肺癌化疗、免疫治疗和检查点阻断的理由：超越传统治疗方法。
J Thorac Oncol. 2013 May;8(5):587-98. doi: 10.1097/JTO.0b013e318286cf88.
7
Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors.免疫疗法在肺癌中的作用：新型疫苗和免疫检查点抑制剂的初步结果。
Asia Pac J Clin Oncol. 2015 Apr;11 Suppl 1:2-8. doi: 10.1111/ajco.12361.
8
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?非小细胞肺癌中PD-1/PD-L1阻断疗法的生物标志物：PD-L1表达是患者选择的良好标志物吗？
Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6.
9
Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer.小细胞肺癌免疫检查点抑制的最新进展与未来策略
Clin Lung Cancer. 2017 Mar;18(2):132-140. doi: 10.1016/j.cllc.2016.07.004. Epub 2016 Jul 9.
10
Immune checkpoint blockade in lung cancer.肺癌中的免疫检查点阻断
Discov Med. 2016 Aug;22(119):55-65.
引用本文的文献
1
The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis.胶质母细胞瘤患者中PD-L1表达的预后意义：一项荟萃分析。
Front Oncol. 2022 Oct 12;12:925560. doi: 10.3389/fonc.2022.925560. eCollection 2022.
2
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC).小细胞肺癌（SCLC）的生物学、管理与治疗进展
Front Oncol. 2020 Jul 16;10:1074. doi: 10.3389/fonc.2020.01074. eCollection 2020.
3
Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling.基于 TNFSF14 和免疫检查点基因表达谱鉴定 GBM 的免疫亚型和预后。
Aging (Albany NY). 2020 Apr 20;12(8):7112-7128. doi: 10.18632/aging.103065.
4
What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?在免疫治疗时代，放疗对于广泛期小细胞肺癌的作用是什么？
Transl Lung Cancer Res. 2019 Sep;8(Suppl 2):S153-S162. doi: 10.21037/tlcr.2019.05.01.
5
RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines.RNA 转录和剪接错误作为癌症移码新抗原疫苗的来源。
Sci Rep. 2019 Oct 2;9(1):14184. doi: 10.1038/s41598-019-50738-4.
6
Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma.共刺激检查点 SLAMF8 是胶质母细胞瘤的一个独立预后因素。
CNS Neurosci Ther. 2019 Mar;25(3):333-342. doi: 10.1111/cns.13041. Epub 2018 Aug 13.
7
Immune checkpoint inhibitors in small cell lung cancer.小细胞肺癌中的免疫检查点抑制剂
J Thorac Dis. 2018 Feb;10(Suppl 3):S460-S467. doi: 10.21037/jtd.2017.12.51.
8
Does the oncology community have a rejection bias when it comes to repurposed drugs?肿瘤学界在看待药物重新利用时是否存在排斥偏见？
Ecancermedicalscience. 2018 Jan 16;12:ed76. doi: 10.3332/ecancer.2018.ed76. eCollection 2018.
9
Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors.免疫疗法与放射疗法联合治疗小细胞肺癌和胸腺瘤。
Transl Lung Cancer Res. 2017 Apr;6(2):186-195. doi: 10.21037/tlcr.2017.03.04.
本文引用的文献
1
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.三期随机临床试验：伊匹单抗联合依托泊苷和铂类药物与安慰剂联合依托泊苷和铂类药物治疗广泛期小细胞肺癌。
J Clin Oncol. 2016 Nov 1;34(31):3740-3748. doi: 10.1200/JCO.2016.67.6601.
2
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合铂类双药化疗用于晚期非小细胞肺癌的一线治疗
J Clin Oncol. 2016 Sep 1;34(25):2969-79. doi: 10.1200/JCO.2016.66.9861. Epub 2016 Jun 27.
3
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.纳武利尤单抗单药治疗及纳武利尤单抗联合伊匹单抗治疗复发性小细胞肺癌（CheckMate 032）：一项多中心、开放标签、Ⅰ/Ⅱ期试验。
Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4.
4
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.克隆性新抗原引发T细胞免疫反应性以及对免疫检查点阻断的敏感性。
Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.
5
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.癌症免疫学。突变图谱决定非小细胞肺癌对程序性死亡受体1（PD-1）阻断治疗的敏感性。
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
6
Left behind? Drug discovery in extensive-stage small-cell lung cancer.被遗忘了？广泛期小细胞肺癌的药物研发
Clin Lung Cancer. 2014 Mar;15(2):93-5. doi: 10.1016/j.cllc.2013.12.010. Epub 2014 Jan 3.
7
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.综合性基因组分析鉴定出小细胞肺癌的重要体细胞驱动突变。
Nat Genet. 2012 Oct;44(10):1104-10. doi: 10.1038/ng.2396. Epub 2012 Sep 2.
8
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.伊匹单抗联合紫杉醇和卡铂作为广泛期小细胞肺癌的一线治疗：一项随机、双盲、多中心 2 期临床试验的结果。
Ann Oncol. 2013 Jan;24(1):75-83. doi: 10.1093/annonc/mds213. Epub 2012 Aug 2.
9
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.伊匹单抗联合紫杉醇和卡铂作为 IIIB/IV 期非小细胞肺癌一线治疗：一项随机、双盲、多中心 II 期研究的结果。
J Clin Oncol. 2012 Jun 10;30(17):2046-54. doi: 10.1200/JCO.2011.38.4032. Epub 2012 Apr 30.
10
The blockade of immune checkpoints in cancer immunotherapy.癌症免疫疗法中的免疫检查点阻断。
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.
Zotero 插件